ESMO Open · 2023 · 42 citations · 29 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyOncology PharmacotherapyConcurrent ChemoradiationNeoadjuvant ChemotherapyNeoadjuvant PharmacotherapyNeoadjuvant TherapyRadiation TherapyResponse AssessmentAdjuvant Concurrent ChemoradiationCapecitabine-based TherapyConcurrent Chemoradiation TherapyNeoadjuvant ChemoradiationNeoadjuvant Concurrent ChemoradiationNeoadjuvant Therapy TrialsRectal Cancer Neoadjuvant TherapyRectal Cancer Radiotherapy
•Neoadjuvant CRT followed by surgery ± adjuvant chemotherapy is the standard treatment of LARC.•However, a high percentage of patients will eventually develop a distant recurrence.•To improve patient outcomes, the use of consolidation durvalumab treatment after standard neoadjuvant CRT was investigated.•A neoadjuvant treatment with durvalumab following CRT showed promising activity and tolerability in the management of LARC. BackgroundThis study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy of locally advanced rectal cancer.Patients and methodsThe PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter study aimed at evaluating the efficacy and safety of preoperative treatment with durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2 twice daily). The primary endpoint was the pathological complete response (pCR) rate; secondary endpoints were the proportion of clinical complete remissions and safety. The sample size was estimated assuming a null pCR proportion of 0.15 and an alternative pCR proportion of 0.30 (α = 0.05, power = 0.80). The proposed treatment could be considered promising if ≥13 pCRs were observed in 55 patients (EudraCT: 2018-004758-39; NCT04083365).ResultsBetween November 2019 and August 2021, 60 patients were accrued, of which 55 were assessable for the study’s objectives. Two patients experienced disease progression during treatment. Nineteen out of 55 eligible patients achieved a pCR (34.5%, 95% confidence interval 22.2% to 48.6%). Regarding toxicity related to durvalumab, grade 3 adverse events (AEs) occurred in four patients (7.3%) (diarrhea, skin toxicity, transaminase increase, lipase increase, and pancolitis). Grade 4 toxicity was not observed. In 20 patients (36.4%), grade 1-2 AEs related to durvalumab were observed. The most common were endocrine toxicity (hyper/hypothyroidism), dermatologic toxicity (skin rash), and gastrointestinal toxicity (transaminase increase, nausea, diarrhea, constipation).ConclusionThis study met its primary endpoint showing that CRT followed by durvalumab could increase pCR with a safe toxicity profile. This combination is a promising, feasible strategy worthy of further investigation. This study investigated the efficacy of chemoradiotherapy (CRT) followed by durvalumab as neoadjuvant therapy of locally advanced rectal cancer. The PANDORA trial is a prospective, phase II, open-label, single-arm, multicenter study aimed at evaluating the efficacy and safety of preoperative treatment with durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2 twice daily). The primary endpoint was the pathological complete response (pCR) rate; secondary endpoints were the proportion of clinical complete remissions and safety. The sample size was estimated assuming a null pCR proportion of 0.15 and an alternative pCR proportion of 0.30 (α = 0.05, power = 0.80). The proposed treatment could be considered promising if ≥13 pCRs were observed in 55 patients (EudraCT: 2018-004758-39; NCT04083365). Between November 2019 and August 2021, 60 patients were accrued, of which 55 were assessable for the study’s objectives. Two patients experienced disease progression during treatment. Nineteen out of 55 eligible patients achieved a pCR (34.5%, 95% confidence interval 22.2% to 48.6%). Regarding toxicity related to durvalumab, grade 3 adverse events (AEs) occurred in four patients (7.3%) (diarrhea, skin toxicity, transaminase increase, lipase increase, and pancolitis). Grade 4 toxicity was not observed. In 20 patients (36.4%), grade 1-2 AEs related to durvalumab were observed. The most common were endocrine toxicity (hyper/hypothyroidism), dermatologic toxicity (skin rash), and gastrointestinal toxicity (transaminase increase, nausea, diarrhea, constipation). This study met its primary endpoint showing that CRT followed by durvalumab could increase pCR with a safe toxicity profile. This combination is a promising, feasible strategy worthy of further investigation.
29
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang et al. · New England Journal of Medicine · 2015 · 9.4K citations · Full text
Life Sciences, Immunology, Oncology +17
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Optimal two-stage designs for phase II clinical trials
Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Jean-François Bosset, Laurence Collette, G. Calais et al. · New England Journal of Medicine · 2006 · 2.7K citations · Full text